MASH - Metabolic Dysfunction-Associated SteatohepatitisPhase 4NCT07848191
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
A Phase 4 study testing Rezdiffra, Resmetirom and ACTOS/pioglitazone in people with MASH - Metabolic Dysfunction-Associated Steatohepatitis, run by Madrigal Pharmaceuticals, Inc. at 16 sites in United States.
Trial summary
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone) Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- What is being tested?
- Rezdiffra, Resmetirom and ACTOS/pioglitazone
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 16 sitesUnited States
- Study dates
- 7 Oct 2026to Nov 2027
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All Subjects:
- Willing to participate in the study and provide written informed consent.
- Meets all requirements per REZDIFFRA Prescribing Information, in the opinion of the PI.
- Male and female adults ≥18 of age at time of screening.
- Evidence of hepatic steatosis consistent with MASH demonstrated by an MRI-PDFF fat fraction >5% obtained during second screening period.
- Evidence of moderate-to-advanced fibrosis (F2-F3) without cirrhosis.
Show all 17Show fewer
- Stable medical conditions and background medications (non-concomitant medications as defined in this protocol) per PI judgement.
- Female subjects of reproductive potential are eligible if they have a negative serum pregnancy test (beta human chorionic gonadotropin), are not breastfeeding, and do not plan to become pregnant during the study and agree to use 1 highly effective birth control method during the study and for at least 30 days after newly introduced medication administration.
- Highly effective birth control methods include hormonal and non-hormonal intrauterine device, combination estrogen-progesterone hormonal contraception (oral, transdermal, or vaginal), tubal ligation, a vasectomized or sterile male partner, or sexual abstinence (defined as refraining from heterosexual intercourse), from Screening throughout the study, and for at least 30 days after newly introduced medication administration. Reliance on abstinence from heterosexual intercourse is acceptable only if it is the subject's habitual practice. NOTE: Female subjects who are not of child-bearing potential (ie, surgically [bilateral oophorectomy, hysterectomy] or naturally sterile [>12 consecutive months without menses]) do not require contraception during the study.
- Must be taking a stable dose of ACTOS/pioglitazone for at least 2 months prior to Baseline. (Group A1)
- Must be taking a stable dose of FARXIGA/dapagliflozin for at least 2 months prior to Baseline. (Group A2)
- Must be taking a stable dose of REZDIFFRA for at least 2 months prior to Baseline. (Groups B1 and B2)
- Must not have previously taken RESMETIROM or ACTOS/pioglitazone or FARXIGA/dapagliflozin. (Group C)
- For Groups A1, B1, and C1: Meets all requirements per ACTOS/pioglitazone Prescribing Information, in the opinion of the PI.
- For Groups B1 and C1: (ie, naïve to ACTOS/pioglitazone): HbA1c at screening ≥7.0% and ≤10.0%.
- For Groups A2, B2, and C2: Meets all requirements per FARXIGA/dapagliflozin Prescribing Information, in the opinion of the PI.
- For Groups B2 and C2 (ie, naïve to FARXIGA/dapagliflozin): HbA1c at screening ≥7.0% and ≤10.0%.
Who cannot join
- Off label use of the commercially available study medications.
- Evidence of cirrhosis demonstrated by clinical, imaging, histologic, or NIT thresholds consistent with cirrhosis.
- Other chronic liver diseases (eg, viral hepatitis, autoimmune hepatitis, hemochromatosis).
- Documented history of decompensated liver disease.
- Use of rosuvastatin or simvastatin at a dose greater than 20 mg/day, or pravastatin or atorvastatin at a dose greater than 40 mg/day, at the time of the first dose of resmetirom. Subjects receiving a statin dose above the applicable limit during the screening period may remain eligible if the dose is reduced to the applicable maximum permitted dose before the first dose of resmetirom.
- Any other condition which, in the opinion of the investigator, would impede compliance, hinder completion of the study, compromise the well-being of the subject, or interfere with the study outcomes.
Show all 13Show fewer
- Active or suspected bladder cancer.
- Diagnosis of heart failure.
- eGFR < 60mL/min/1.73 m2
- Developmental/intellectual disability, limited capacity of recognition, any history of clinically important emotional and/or psychiatric illness, inability to follow the study procedures, or any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.
- Individuals who are currently incarcerated or who are anticipated to be incarcerated during the study period.
- Groups B and C:
- Unable to secure a prescription for a concomitant medication.
Trial locations and contacts
16 sites in 1 country. Contact the study team or a site near you to ask about taking part.
16 sites in 1 country
United States16 sites, 16 recruiting
- Not yet recruiting
Texas Clinical Research Institute
Arlington, Texas, 76012-3216
- Not yet recruiting
Arizona Liver Health - Chandler
Chandler, Arizona, 85224
- Not yet recruiting
University Diabetes and Endocrine Consultants
Chattanooga, Tennessee, 37411
- Recruiting
Gastro Health Research
Cincinnati, Ohio, 45219
- Not yet recruiting
Southern California Research Center
Coronado, California, 92118
- Not yet recruiting
South Texas Endocrinology & Metabolism Center
Corpus Christi, Texas, 78414
- Not yet recruiting
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas, 75234
- Recruiting
Elevate Clinical Research
Lake Charles, Louisiana, 70605
- Not yet recruiting
Florida Research Institute
Lakewood Rch, Florida, 34211
- Not yet recruiting
Elevate Clinical Research - McAllen - PPDS
McAllen, Texas, 78504
- Recruiting
Gastro Health PLLC Galloway
Miami, Florida, 33176
- Not yet recruiting
Med Research of Florida, LLC
Miami, Florida, 33186
- Not yet recruiting
Centricity Research - Morehead City - Multispecialty - PPDS
Morehead City, North Carolina, 28557
- Not yet recruiting
Arkansas Gastroenterology
North Little Rock, Arkansas, 72117
- Not yet recruiting
Inland Empire Liver Foundation
Rialto, California, 37411
- Not yet recruiting
Diabetes and Glandular Disease Clinic, PA
San Antonio, Texas, 78229
About this study
Official title: A Phase 4, Open-label, Multi-group Study of Rezdiffra® in Combination With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and Moderate to Advanced (F2-F3) Fibrosis, Administered According to Their Approved Labeling
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)
Read the detailed description
This Phase 4 study will evaluate the safety and tolerability of REZDIFFRA® (resmetirom) when used in combination with concomitant therapies commonly used to treat diabetes in adults with metabolic dysfunction-associated steatohepatitis (MASH) and noncirrhotic, moderate-to-advanced (F2-F3) fibrosis. The concomitant therapies evaluated in this study will include ACTOS®/pioglitazone and FARXIGA®/dapagliflozin. All study medications will be administered according to their approved labeling.
Participants will be assigned to one of six cohorts based on their existing therapy and the concomitant medication being evaluated. In Group A, participants who are receiving a stable dose of pioglitazone or dapagliflozin will initiate resmetirom. In Group B, participants who are receiving a stable dose of REZDIFFRA will initiate pioglitazone or dapagliflozin. In Group C, participants who are not currently receiving either treatment will initiate resmetirom and either pioglitazone or dapagliflozin in a staggered manner, with a 4- to 6-week run-in period between initiation of the first and second medications.
Approximately 25 participants are planned for each of the six cohorts, for a maximum planned enrollment of approximately 150 participants. Following initiation of combination treatment, participants will be followed for 24 weeks, with a safety follow-up visit approximately 4 weeks after completion of treatment.
Safety and tolerability will be characterized through assessment of treatment-emergent adverse events, physical examinations, vital signs, clinical laboratory parameters, treatment discontinuations, and dose interruptions or reductions. Exploratory assessments will evaluate changes in liver fat by MRI-PDFF, noninvasive measures of hepatic steatosis and fibrosis, and biomarkers related to MASH disease state, insulin resistance, glucose homeostasis, body weight, and liver function.
- Being tested
- Rezdiffra, Resmetirom, ACTOS/pioglitazone, FARXIGA/dapagliflozin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RezdiffraDrug
All study medications will be administered according to their labels:
- REZDIFFRA- Label weight-based dosing:
- <100 kg: 80 mg orally once daily.
- ≥100 kg: 100 mg orally once daily
ResmetiromDrug
Resmetirom - weight-based dosing:
- <100 kg: 80 mg orally once daily.
- ≥100 kg: 100 mg orally once daily
ACTOS/pioglitazoneDrug
Label dosing recommendations indicated for patients without congestive heart failure (15 or 30 mg orally once daily; if tolerated, increase by 15 mg increments up to a maximum of 45 mg orally once daily for additional glycemic control
FARXIGA/dapagliflozinDrug
Label dosing recommendations indicated for glycemic control in type 2 diabetes (5 mg orally once daily; if tolerated, increase to 10 mg orally once daily for additional glycemic control)
| Study group | Role | What they receive |
|---|---|---|
| Actos (pioglitazone) [Ongoing] | Resmetirom [New] | Other | Experienced Actos/Pioglitazone + Resmetirom Naive (A1) Receives: Drug: Resmetirom; Drug: ACTOS/pioglitazone |
| Farxiga (dapagliflozin) [Ongoing] | Resmetirom [New] | Other | Experienced Farxiga/Dapagliflozin + Resmetirom Naive (A2) Receives: Drug: Resmetirom; Drug: FARXIGA/dapagliflozin |
| REZDIFFRA [Ongoing] | Actos (pioglitazone) [New] | Other | Experienced REZDIFFRA + Actos/Pioglitazone Naive (B1) Receives: Drug: Rezdiffra; Drug: ACTOS/pioglitazone |
| REZDIFFRA [Ongoing] | Farxiga (dapagliflozin) [New] | Other | Experienced REZDIFFRA + Farxiga/Dapagliflozin Naive (B2) Receives: Drug: Rezdiffra; Drug: FARXIGA/dapagliflozin |
| Actos (pioglitazone) [New] | Resmetirom [New] | Other | Naive Actos/Pioglitazone + Resmetirom Naive (C2) Receives: Drug: Resmetirom; Drug: ACTOS/pioglitazone |
| Farxiga (dapagliflozin) [New] | Resmetirom [New] | Other | Naïve Farxiga/dapagliflozin + Resmetirom Naïve (C2) Receives: Drug: Resmetirom; Drug: FARXIGA/dapagliflozin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number and Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
The total number of TEAEs and the number and percentage of participants with at least 1 TEAE will be summarized by study group. TEAEs will also be summarized by System Organ Class and Preferred Term.
Measured: From First Dose of newly introduced medication up to 28 weeks
Number and Percentage of Participants With TEAEs by Maximum Severity
The number and percentage of participants with TEAEs will be summarized by maximum severity using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
Measured: From First Dose of newly introduced medication up to 28 weeks
Number and Percentage of Participants With TEAEs by Relationship to Study Medication
The number and percentage of participants with TEAEs assessed as Related or Not Related to each applicable study medication (REZDIFFRA/resmetirom, ACTOS/pioglitazone, or FARXIGA/dapagliflozin) will be summarized by study group.
Measured: From First Dose of newly introduced medication up to 28 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2026
- Study start7 Oct 2026
- Primary completionNov 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MASH - Metabolic Dysfunction-Associated SteatohepatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Tom Hare, Study director, Madrigal Pharmaceuticals, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07848191
- Sponsor's protocol ID
- MGL-3196-33
- Status last verified
- Oct 2026
- First submitted
- 25 Aug 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 4, Open-label, Multi-group Study of Rezdiffra® in Combination With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and Moderate to Advanced (F2-F3) Fibrosis, Administered According to Their Approved Labeling
- ClinicalTrials.gov ID
- NCT07848191
- Acronym / sponsor ID
- MGL-3196-33
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- 7 Oct 2026 (actual)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 29 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)
Detailed description
This Phase 4 study will evaluate the safety and tolerability of REZDIFFRA® (resmetirom) when used in combination with concomitant therapies commonly used to treat diabetes in adults with metabolic dysfunction-associated steatohepatitis (MASH) and noncirrhotic, moderate-to-advanced (F2-F3) fibrosis. The concomitant therapies evaluated in this study will include ACTOS®/pioglitazone and FARXIGA®/dapagliflozin. All study medications will be administered according to their approved labeling.
Participants will be assigned to one of six cohorts based on their existing therapy and the concomitant medication being evaluated. In Group A, participants who are receiving a stable dose of pioglitazone or dapagliflozin will initiate resmetirom. In Group B, participants who are receiving a stable dose of REZDIFFRA will initiate pioglitazone or dapagliflozin. In Group C, participants who are not currently receiving either treatment will initiate resmetirom and either pioglitazone or dapagliflozin in a staggered manner, with a 4- to 6-week run-in period between initiation of the first and second medications.
Approximately 25 participants are planned for each of the six cohorts, for a maximum planned enrollment of approximately 150 participants. Following initiation of combination treatment, participants will be followed for 24 weeks, with a safety follow-up visit approximately 4 weeks after completion of treatment.
Safety and tolerability will be characterized through assessment of treatment-emergent adverse events, physical examinations, vital signs, clinical laboratory parameters, treatment discontinuations, and dose interruptions or reductions. Exploratory assessments will evaluate changes in liver fat by MRI-PDFF, noninvasive measures of hepatic steatosis and fibrosis, and biomarkers related to MASH disease state, insulin resistance, glucose homeostasis, body weight, and liver function.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Actos (pioglitazone) [Ongoing] | Resmetirom [New] | Other | Drug: Resmetirom, Drug: ACTOS/pioglitazoneExperienced Actos/Pioglitazone + Resmetirom Naive (A1) |
| Farxiga (dapagliflozin) [Ongoing] | Resmetirom [New] | Other | Drug: Resmetirom, Drug: FARXIGA/dapagliflozinExperienced Farxiga/Dapagliflozin + Resmetirom Naive (A2) |
| REZDIFFRA [Ongoing] | Actos (pioglitazone) [New] | Other | Drug: Rezdiffra, Drug: ACTOS/pioglitazoneExperienced REZDIFFRA + Actos/Pioglitazone Naive (B1) |
| REZDIFFRA [Ongoing] | Farxiga (dapagliflozin) [New] | Other | Drug: Rezdiffra, Drug: FARXIGA/dapagliflozinExperienced REZDIFFRA + Farxiga/Dapagliflozin Naive (B2) |
| Actos (pioglitazone) [New] | Resmetirom [New] | Other | Drug: Resmetirom, Drug: ACTOS/pioglitazoneNaive Actos/Pioglitazone + Resmetirom Naive (C2) |
| Farxiga (dapagliflozin) [New] | Resmetirom [New] | Other | Drug: Resmetirom, Drug: FARXIGA/dapagliflozinNaïve Farxiga/dapagliflozin + Resmetirom Naïve (C2) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Willing to participate in the study and provide written informed consent.
- Meets all requirements per REZDIFFRA Prescribing Information, in the opinion of the PI.
- Male and female adults ≥18 of age at time of screening.
- Evidence of hepatic steatosis consistent with MASH demonstrated by an MRI-PDFF fat fraction >5% obtained during second screening period.
- Evidence of moderate-to-advanced fibrosis (F2-F3) without cirrhosis.
Key exclusion criteria (13 listed)
- Off label use of the commercially available study medications.
- Evidence of cirrhosis demonstrated by clinical, imaging, histologic, or NIT thresholds consistent with cirrhosis.
- Other chronic liver diseases (eg, viral hepatitis, autoimmune hepatitis, hemochromatosis).
- Documented history of decompensated liver disease.
- Use of rosuvastatin or simvastatin at a dose greater than 20 mg/day, or pravastatin or atorvastatin at a dose greater than 40 mg/day, at the time of the first dose of resmetirom. Subjects receiving a statin dose above the applicable limit during the screening period may remain eligible if the dose is reduced to the applicable maximum permitted dose before the first dose of resmetirom.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RezdiffraAll study medications will be administered according to their labels: • REZDIFFRA- Label weight-based dosing: * <100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily | Drug | REZDIFFRA [Ongoing] | Actos (pioglitazone) [New], REZDIFFRA [Ongoing] | Farxiga (dapagliflozin) [New] |
| ResmetiromResmetirom - weight-based dosing: * <100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily | Drug | Actos (pioglitazone) [New] | Resmetirom [New], Actos (pioglitazone) [Ongoing] | Resmetirom [New], Farxiga (dapagliflozin) [New] | Resmetirom [New], Farxiga (dapagliflozin) [Ongoing] | Resmetirom [New] |
| ACTOS/pioglitazoneLabel dosing recommendations indicated for patients without congestive heart failure (15 or 30 mg orally once daily; if tolerated, increase by 15 mg increments up to a maximum of 45 mg orally once daily for additional glycemic control | Drug | Actos (pioglitazone) [New] | Resmetirom [New], Actos (pioglitazone) [Ongoing] | Resmetirom [New], REZDIFFRA [Ongoing] | Actos (pioglitazone) [New] |
| FARXIGA/dapagliflozinLabel dosing recommendations indicated for glycemic control in type 2 diabetes (5 mg orally once daily; if tolerated, increase to 10 mg orally once daily for additional glycemic control) | Drug | Farxiga (dapagliflozin) [New] | Resmetirom [New], Farxiga (dapagliflozin) [Ongoing] | Resmetirom [New], REZDIFFRA [Ongoing] | Farxiga (dapagliflozin) [New] |
Primary outcome
Number and Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: From First Dose of newly introduced medication up to 28 weeks
The total number of TEAEs and the number and percentage of participants with at least 1 TEAE will be summarized by study group. TEAEs will also be summarized by System Organ Class and Preferred Term.
Number and Percentage of Participants With TEAEs by Maximum Severity
Time frame: From First Dose of newly introduced medication up to 28 weeks
The number and percentage of participants with TEAEs will be summarized by maximum severity using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
Number and Percentage of Participants With TEAEs by Relationship to Study Medication
Time frame: From First Dose of newly introduced medication up to 28 weeks
The number and percentage of participants with TEAEs assessed as Related or Not Related to each applicable study medication (REZDIFFRA/resmetirom, ACTOS/pioglitazone, or FARXIGA/dapagliflozin) will be summarized by study group.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for MASH - Metabolic Dysfunction-Associated Steatohepatitis
RecruitingPhase 2
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Recruiting
Exercise for an Aging Liver (EXALIVER)
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASH - Metabolic Dysfunction-Associated Steatohepatitis
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Not yet recruitingPhase 2
To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tom Hare study director
Madrigal Pharmaceuticals, Inc.
16 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Rezdiffra, Resmetirom and ACTOS/pioglitazone in people with MASH - Metabolic Dysfunction-Associated Steatohepatitis, run by Madrigal Pharmaceuticals, Inc. at 16 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 16 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tom Hare (267-406-0611, info@madrigalpharma.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number and Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) (time frame: From First Dose of newly introduced medication up to 28 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.